A novel viral system for generating antigen-specific T cells.
about
Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunizationDifferential Induction of Type I Interferon Responses in Myeloid Dendritic Cells by Mosquito and Mammalian-Cell-Derived AlphavirusesAn Immunogenic and Protective Alphavirus Replicon Particle-Based Dengue Vaccine Overcomes Maternal Antibody Interference in Weanling MiceInduction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2High epitope expression levels increase competition between T cellsA two-phase innate host response to alphavirus infection identified by mRNP-tagging in vivo.Principles of adoptive T cell cancer therapy.An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal miceMucosal and systemic adjuvant activity of alphavirus replicon particles.A tetravalent alphavirus-vector based dengue vaccine provides effective immunity in an early life mouse modelAerosolized Ebola vaccine protects primates and elicits lung-resident T cell responsesVenezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.Infected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particlesVaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge.The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines.Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen.Eastern and Venezuelan equine encephalitis viruses differ in their ability to infect dendritic cells and macrophages: impact of altered cell tropism on pathogenesis.Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice.Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects.A human dendritic cell subset receptive to the Venezuelan equine encephalitis virus-derived replicon particle constitutively expresses IL-32.Enterovirus 71 infection of human dendritic cells.N-linked glycans on dengue viruses grown in mammalian and insect cellsEffects of rapid antigen degradation and VEE glycoprotein specificity on immune responses induced by a VEE replicon vaccine.Nonspreading Rift Valley Fever Virus Infection of Human Dendritic Cells Results in Downregulation of CD83 and Full Maturation of Bystander Cells.Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy.Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses.VRP immunotherapy targeting neu: treatment efficacy and evidence for immunoediting in a stringent rat mammary tumor model.Dendritic Cell-Based Immunotherapy
P2860
Q24634730-C9C343C7-4427-41C4-BA6C-719842F2E2A8Q27478027-BD707165-5F78-45C6-9BEF-4EA3718F5293Q27481478-0938FF19-B958-4A22-95F9-6F49AE3CD92DQ27486582-85D41629-7DC4-4B79-B63B-D52923F0F518Q33255329-2343C12B-C16D-4F1F-B988-FF38E71D52ADQ33316163-0233FBCF-2657-42B2-AD49-F48DF8CD2020Q34003932-36981027-F47F-49FC-AA57-011FB4D2AB5DQ34059308-3F662697-D02B-4165-ACB3-8143CBE3751AQ34410789-14D80111-2802-4A19-BF7D-9E8135C11753Q35806060-B5248A9A-4C99-4D53-8AEC-E25F0E296B64Q36040533-7EF26E5C-9F1A-4C6F-A449-7F6951381514Q36315159-6D663F38-150A-4E8F-B98D-78531B6ECE5CQ36458651-6FF49479-0728-41B6-9D33-75CA6F6A96CBQ36488876-B3321FD3-0A56-4892-9E47-946071B9B91AQ36677419-5D291568-08C8-4591-BAF1-141152267740Q36716920-976ADEDF-DE75-4152-A1F0-AB9487C2AF90Q36949568-8288B369-6A0E-427A-B23F-BB2462A3E44BQ37216446-071492ED-F2AD-4D6D-91E3-B1FA14232ECFQ37416110-B9E28E6D-466A-4E28-8C61-7B14AF0F82DFQ38287790-FDF0F4D9-72F7-4B88-9CCE-E4C75D19266AQ39825846-6FA45766-D504-49CE-BDC1-618A5520AC49Q39843134-2F68AF16-E723-453B-8AD9-227B96BCBC41Q40074644-635193BA-1CC6-4AC6-AA7F-2E0CFF1ACC79Q40130716-5AD4E0CF-3D0F-4017-B25B-0CA4E73DB07CQ40151111-8C69699D-8E1F-4058-9BE7-08BF8133876DQ40707492-5DF86B20-FCD9-4E57-B43F-24B1809AB333Q44430660-C450E63B-4A78-4DD8-9EAD-8115CFC925B1Q58409682-CB9D0126-5CCA-4797-8F07-3AB1DB6C2FEB
P2860
A novel viral system for generating antigen-specific T cells.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
A novel viral system for generating antigen-specific T cells.
@en
type
label
A novel viral system for generating antigen-specific T cells.
@en
prefLabel
A novel viral system for generating antigen-specific T cells.
@en
P2093
P1476
A novel viral system for generating antigen-specific T cells.
@en
P2093
Karen P McKinnon
Martha Collier
Nancy L Davis
Robert E Johnston
Timothy P Moran
P304
P356
10.4049/JIMMUNOL.175.5.3431
P407
P577
2005-09-01T00:00:00Z